Cargando…
Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
To investigate the effect of both prostate volume and serum testosterone changes on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy. A total of 167 patients who received androgen deprivation therapy for prostate cancer treatment from January 2010...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630373/ https://www.ncbi.nlm.nih.gov/pubmed/36323749 http://dx.doi.org/10.1038/s41598-022-21963-1 |
_version_ | 1784823589064671232 |
---|---|
author | Bang, Woo Jin Kim, Hwanik Oh, Cheol Young Jo, Jung Ki Cho, Jin Seon Shim, Myungsun |
author_facet | Bang, Woo Jin Kim, Hwanik Oh, Cheol Young Jo, Jung Ki Cho, Jin Seon Shim, Myungsun |
author_sort | Bang, Woo Jin |
collection | PubMed |
description | To investigate the effect of both prostate volume and serum testosterone changes on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy. A total of 167 patients who received androgen deprivation therapy for prostate cancer treatment from January 2010 to August 2020 were enrolled in this retrospective study. Changes in the International Prostate Symptom Score (IPSS) in the patient groups stratified by prostate volume and the amount of testosterone reduction were assessed every 4 weeks until 12 weeks after androgen deprivation therapy initiation. Longitudinal mixed models were used to assess the adjusted effects of prostate volume and testosterone reduction on IPSS change. All mean values of IPSS-total score (IPSS-total), voiding subscore (IPSS-vs), and storage subscore (IPSS-ss) significantly decreased from baseline to week 12 in both patients with small (< 33 mL) and large (≥ 33 mL) prostates. The mean values of IPSS-total, IPSS-vs, and IPSS-ss similarly decreased in patients with large prostate with a baseline IPSS-total of ≥ 13. However, in those with small prostate, IPSS-ss specifically remained unchanged, while IPSS-total and IPSS-vs significantly decreased. In addition, only in patients with small prostate (< 33 mL), patients with lesser testosterone reduction (< Δ400 ng/dL) showed greater improvement in IPSS-ss by 7.5% compared with those with greater testosterone reduction (≥ Δ400 ng/dL). In conclusion, although androgen deprivation therapy generally improves lower urinary tract symptoms, it may worsen specifically storage symptoms in patients with relatively small prostate and greater testosterone reduction. Our finding suggests that testosterone may influence lower urinary tract symptoms in these patients. |
format | Online Article Text |
id | pubmed-9630373 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-96303732022-11-04 Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy Bang, Woo Jin Kim, Hwanik Oh, Cheol Young Jo, Jung Ki Cho, Jin Seon Shim, Myungsun Sci Rep Article To investigate the effect of both prostate volume and serum testosterone changes on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy. A total of 167 patients who received androgen deprivation therapy for prostate cancer treatment from January 2010 to August 2020 were enrolled in this retrospective study. Changes in the International Prostate Symptom Score (IPSS) in the patient groups stratified by prostate volume and the amount of testosterone reduction were assessed every 4 weeks until 12 weeks after androgen deprivation therapy initiation. Longitudinal mixed models were used to assess the adjusted effects of prostate volume and testosterone reduction on IPSS change. All mean values of IPSS-total score (IPSS-total), voiding subscore (IPSS-vs), and storage subscore (IPSS-ss) significantly decreased from baseline to week 12 in both patients with small (< 33 mL) and large (≥ 33 mL) prostates. The mean values of IPSS-total, IPSS-vs, and IPSS-ss similarly decreased in patients with large prostate with a baseline IPSS-total of ≥ 13. However, in those with small prostate, IPSS-ss specifically remained unchanged, while IPSS-total and IPSS-vs significantly decreased. In addition, only in patients with small prostate (< 33 mL), patients with lesser testosterone reduction (< Δ400 ng/dL) showed greater improvement in IPSS-ss by 7.5% compared with those with greater testosterone reduction (≥ Δ400 ng/dL). In conclusion, although androgen deprivation therapy generally improves lower urinary tract symptoms, it may worsen specifically storage symptoms in patients with relatively small prostate and greater testosterone reduction. Our finding suggests that testosterone may influence lower urinary tract symptoms in these patients. Nature Publishing Group UK 2022-11-02 /pmc/articles/PMC9630373/ /pubmed/36323749 http://dx.doi.org/10.1038/s41598-022-21963-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Bang, Woo Jin Kim, Hwanik Oh, Cheol Young Jo, Jung Ki Cho, Jin Seon Shim, Myungsun Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy |
title | Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy |
title_full | Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy |
title_fullStr | Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy |
title_full_unstemmed | Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy |
title_short | Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy |
title_sort | clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630373/ https://www.ncbi.nlm.nih.gov/pubmed/36323749 http://dx.doi.org/10.1038/s41598-022-21963-1 |
work_keys_str_mv | AT bangwoojin clinicalsignificanceofprostatevolumeandtestosteronereductiononlowerurinarytractsymptomsinpatientswithprostatecancerundergoingandrogendeprivationtherapy AT kimhwanik clinicalsignificanceofprostatevolumeandtestosteronereductiononlowerurinarytractsymptomsinpatientswithprostatecancerundergoingandrogendeprivationtherapy AT ohcheolyoung clinicalsignificanceofprostatevolumeandtestosteronereductiononlowerurinarytractsymptomsinpatientswithprostatecancerundergoingandrogendeprivationtherapy AT jojungki clinicalsignificanceofprostatevolumeandtestosteronereductiononlowerurinarytractsymptomsinpatientswithprostatecancerundergoingandrogendeprivationtherapy AT chojinseon clinicalsignificanceofprostatevolumeandtestosteronereductiononlowerurinarytractsymptomsinpatientswithprostatecancerundergoingandrogendeprivationtherapy AT shimmyungsun clinicalsignificanceofprostatevolumeandtestosteronereductiononlowerurinarytractsymptomsinpatientswithprostatecancerundergoingandrogendeprivationtherapy |